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Abstract
Background: Killer-cell Immunoglobulin-like Receptors(KIR) interact with Human Leukocyte Antigen(HLA) to modify
natural killer- and T-cell function. KIR are implicated in HIV acquisition by small studies that have not been widely
replicated. A role for KIR in HIV disease progression is more widely replicated and supported by functional studies.
Methods: To assess the role of KIR and KIR ligands in HIV acquisition and disease course, we studied at-risk women
in South Africa between 2004–2010. Logistic regression was used for nested case–control analysis of 154 women who
acquired vs. 155 who did not acquire HIV, despite high exposure. Linear mixed-effects models were used for cohort
analysis of 139 women followed prospectively for a median of 54 months (IQR 31–69) until 2014.
Results: Neither KIR repertoires nor HLA alleles were associated with HIV acquisition. However, KIR haplotype BB was
associated with lower viral loads (−0.44log10 copies/ml;SE = 0.18;p = 0.03) and higher CD4+ T-cell counts(+80 cells/
μl;SE = 42;p = 0.04). This was largely explained by the protective effect of KIR2DL2/KIR2DS2 on the B haplotype and
reciprocal detrimental effect of KIR2DL3 on the A haplotype.
Conclusions: Although neither KIR nor HLA appear to have a role in HIV acquisition, our data are consistent with
involvement of KIR2DL2 in HIV control. Additional studies to replicate these findings are indicated.
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Background
An array of host genetic factors have been reported to alter
HIV acquisition or markers of HIV disease progression
[1, 2]. Identifying and understanding these genetic corre-
lates may accelerate preventive and therapeutic efforts.
The most widely replicated correlates of HIV acquisition
include homozygosity in the 32-base pair deletion in
CCR5 that reduces acquisition risk. Although, in compari-
son, greater effort has been focused on identifying corre-
lates of HIV disease progression there are similarly only a
handful of widely replicated findings. Natural Killer (NK)
cell and CD8+ T-cell responses stand out as being repro-
ducibly implicated in HIV control [3]. Concordantly,
variation in the Human Leukocyte Antigen (HLA) and
Killer-cell Immunoglobulin-like Receptor (KIR) loci, the
two most polymorphic regions of the human genome that
encode receptors involved in NK and CD8+ T-cell func-
tion, is associated with rates of HIV disease progression
across several studies [2]. Genome-wide association stud-
ies identify HLA-B*57 alleles, and variants that affect
HLA-C expression [4–6] as important modifiers of HIV
viraemia, the former of which had been identified in many
earlier candidate gene studies.
Natural Killer cells are amongst the earliest responders
to viral infection and mediate protective responses by se-
creting pro-inflammatory cytokines and by direct cytolysis
of infected cells. Their function is governed, at least in part,
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by the combinatorial array of inhibitory and activating re-
ceptors including the KIR, Leukocyte immunoglobulin-like
receptors (LILR), the C-type lectin receptors-NKG2A-F,
and the natural cytotoxic receptors (NCRs) -NKp30,
NKp44 and NKp46. The dominant regulators of NK cell
recognition of virus-infected cells are thought to be KIR,
because these are the natural receptors for HLA class I [7].
Alteration in HLA expression and presentation of
pathogen-derived or self-peptides is a common feature
of many viral infections [8]. Diversity in KIR gene con-
tent, polymorphism and structural variation within the
14 KIR genes, and variation in expression confer add-
itional variation in the ability of NK cells to identify and
respond to virus-infected cells. KIRs show partial specifi-
city in their recognition of HLA ligands: KIR3DL1 and
KIR3DS1 recognise HLA-A and HLA-B molecules with
the Bw4 epitope, KIR2DL1 recognises HLA-C molecules
of the C2 group exclusively, KIR2DL3 recognises HLA-C
of the C1 group exclusively and KIR2DL2 recognizes
HLA-C of both C1 and C2 groups. The KIR genes segre-
gate in two groups of haplotypes. Group A haplotypes
consist of nine genes that encode predominantly inhibi-
tory receptors, whereas group B haplotypes represent a
more diverse collection of haplotypes based on gene con-
tent and contain more activating KIRs compared with
haplotype A.
Several combinations of KIR and HLA have been associ-
ated with protection from HIV acquisition [9–13], though
these findings are based on small sample sizes and none
have been replicated in the literature. In contrast, a large
study reported in 2002, found that KIR3DS1 together with
HLA Bw4 alleles encoding Isoleucine at position 80 (80I)
are associated with slower disease progression [5]. Several
additional lines of evidence from subsequent observational
and functional studies support a role for KIR in HIV con-
trol. NK cells are expanded in primary HIV infection [14],
the expansion is modified by specific KIR and ligand rep-
ertoires [15], the degree of HLA C ligand expression asso-
ciates with protection [4, 16] and viruses sequenced from
individuals with specific KIR show evidence of ‘escape’
mutation at sites that appear to alter recognition by KIR
[17]. As in infection with EBV [18], CMV [19], HCV or
HTLV-1 [20], KIR have also been shown to modulate T-
cell responses to HIV [21].
We studied the role of HLA and KIR on risk of HIV ac-
quisition and course of HIV viraemia and CD4+ T-cell
counts through the first 5–10 years of infection in South
African women infected with HIV-1 clade C in a nested
case–control and prospective cohort study respectively. In
prior studies in this cohort we have reported that a) innate
immune cell activation is associated with enhanced HIV
acquisition [22]; b) HIV-directed NK cells secreting IFN-y
are associated with reduced HIV acquisition risk [23]; c)
HIV acquisition results in profound alteration in NK cell
function [24] and d) the rate of HIV disease progression is
more rapid than similar cohorts elsewhere [25, 26]. This
current study strongly implicates KIR2DL2, belonging to
the group B haplotype with HIV control.
Methods
Study design and cohort accrual
Between 2004 and 2010, we prospectively enrolled and
followed-up women at risk for HIV acquisition in studies
[27–29] conducted at two urban and one rural site in
KwaZulu-Natal, South Africa (Fig. 1) [26]. We performed
two analyses of KIR/HLA genetic profiles: a nested case–
control analysis of HIV acquisition and a prospective co-
hort analysis of involvement in HIV disease course. For
the nested case–control analysis we compared 154 women
who acquired HIV to 155 who did not and for the cohort
analysis, studied 139 women with viral load and CD4+ T-
cell count measures.
Women at risk for HIV were extensively counselled on
HIV risk reduction and provided with condoms in line with
the highest standard of counselling at the time [27–29].
The median age at enrolment was 21 years (IQR 20–26
years). As previously reported [30], women who acquired
HIV were younger than those who remained HIV negative
(median age 23, IQR 20–26 vs. median age 33, IQR 25–40).
All except one woman in this study self-identified as black-
African of Zulu ethnicity.
During follow-up in the AI study, clinical care was of-
fered as per contemporary South African treatment guide-
lines including combination antiretroviral therapy when
clinically indicated or if the CD4+ T-cell count declined to
below 200 cells/μl or 350 cells/μl (updated according to
evolving treatment guidelines). Participants were seen ac-
cording to the following schedule: weekly to fortnightly
for the first 3 months post HIV acquisition, monthly from
months 3–12 and quarterly thereafter. At each visit
women received comprehensive prevention counselling,
clinical examination, viral load and CD4+ T-cell count
measurements and additional clinically indicated investi-
gations performed at an accredited laboratory (ISO15189)
using previously described methods [28, 29, 31]. The last
possible date of censorship in those who did not reach a
progression endpoint was 1 August 2014. Women were
censored at time of combination antiretroviral therapy
(cART) initiation, death, loss to follow-up or withdrawal
from the study.
Ethics statement
Participants gave their written and informed consent to
participation in each study according to protocols approved
by the Biomedical Research Ethics Committee of the Uni-
versity of KwaZulu-Natal (Ref 050/051, E013/04, E111/06),
and relevant collaborating centres (University of Cape
Town 025/2004, University of Witwatersrand M040202).
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The protocol under which analyses in this study are con-
ducted was independently approved by the Biomedical
Research Ethics Committee of the University of KwaZulu-
Natal (BE073/10).
KIR and HLA typing
Killer-cell immunoglobulin-like receptor genotyping was
conducted in samples from 154 HIV-positive women and
155 HIV-negative women by sequence-specific oligo-
nucleotide primer PCR or qPCR according to previously
described methods [5, 32]. The definitions used to assign
KIR haplotypes based on gene content were based on pre-
vious reports [7] and are described in detail in Additional
file 1. Individuals having only and all genes of following
group were denoted as having AA: KIR3DL3, KIR2DL3,
KIR2DL1, KIR2DP1, KIR3DP1, KIR2DL4, KIR3DL1, KIR2
DS4, KIR3DL2. Individuals lacking any of the following
were denoted as BB: KIR2DL1, KIR2DL3, KIR3DL1, KIR2
DS4. Individuals having all A haplotype genes and any
1 of the following genes were presumed to be AB: KIR
2DL2, KIR2DL5, KIR2DS1, KIRDS2, KIR2DS3, KIR
2DS5, KIR3DS1. Four-digit HLA typing was performed
as previously described. Further information on classi-
fication of HLA alleles into Bw4 groups and C1/C2
groups is given in Additional file 1.
Outcome definition
Methods of HIV diagnosis and estimation of the date of
acquisition have been previously reported [27, 29]. Plasma
HIV viral load was assessed by Roche Ampliprep/Ampli-
cor or Roche Taqman (Roche Diagnostics, New Jersey,
USA). CD4+ T-cell count enumeration in whole blood
was performed by the TruCOUNT method on a FACSCa-
libur instrument (BD Biosciences, San Jose, USA). The
median number of viral load and CD4+ T-cell count mea-
sures contributed per participant was 29 (IQR 22–34).
Fig. 1 Cohort accrual diagram and study design. The figure shows the three parent studies [27–29] in which HIV negative donors were enrolled,
counselled on HIV risk reduction and followed-up prospectively and how the nested case–control subset was accrued. For the case control analysis of
HIV acquisition, 154 women who acquired HIV were compared with 155 women who remained HIV negative through follow-up. For cohort analyses
of HIV course, 154 women who acquired HIV and were followed up for up to 120 months were studied. Follow-up time and disposition as at 1 August
2014 (date of censorship), is shown in the lower panel for each donor where dot color denotes disposition (green: remains in follow-up, red: exited
study as commenced cART or death, black:lost to follow-up)
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Statistical methods
Statistical analyses were performed according to an a
priori statistical analysis plan (Additional file 1) with
minor amendments made to update KIR haplotype defi-
nitions. For comparisons between women who acquired
HIV and those who did not, logistic regression models
were employed.
To accommodate potential inter- and intra-patient
sources of variation we used linear mixed-effects models
to study potential correlates of HIV viral load and CD4+
T-cell count decline because of their flexibility in allow-
ing for possible heterogeneity in population, and potential
imbalance in the longitudinal data. Graphical plotting of
individual measures was performed using R software, and
locally weighted scatterplot smoothing (LOWESS) was
employed to derive aggregate curves. Analyses were per-
formed in R using the following packages ‘lme4’, ‘survival’,
‘ggplot2’, ‘rms’ and ‘LDheatmap’. P-values presented are
nominal (unadjusted) p-values unless otherwise stated.
Results
Cohort accrual
Between May 2004 and March 2010, 1924 HIV negative
women at risk for HIV acquisition were enrolled in one of
three cohort studies in KwaZulu-Natal, South Africa and
followed up to identify incident infection (Fig. 1). During a
median of 16 months of active follow-up (IQR 7.8–
23.7 months) with monthly or quarterly screening for
HIV, 184 women acquired HIV (HIV incidence rate: 7.63
per 100 PY; 95 % CI 6.59–8.78). Of these, 160 women (of
whom 154 were KIR-genotyped) consented to inclusion in
continued follow-up and were enrolled at a median of 42
(IQR 28–62) days post infection into the CAPRISA AI
study. As at August 2014, the median follow-up was 54
(IQR 31–69) months and at this point 8 were lost to fol-
low up, 8 had died, 1 withdrew from the study, 101 com-
menced cART at a median of 50 (IQR 32–65) months
after infection and 42 remain in follow-up. For cohort
analyses we excluded 15 individuals due to missing data,
leaving 139 individuals with follow up data. The cumula-
tive follow-up time was 629.3 woman-years.
Neither KIR nor HLA profiles are associated with HIV
acquisition
To test whether KIR-HLA profiles are associated with risk
of HIV acquisition we compared KIR gene content, and
HLA alleles among 154 women (cases) who acquired HIV
to 155 women (controls) who did not acquire infection
during follow-up. With this sample size we had 80 %
power to detect predictors with odds ratio <0.63 or >1.6 at
α = 5 % given the cohort HIV incidence of ~7 %. The fre-
quency of KIR genes, HLA alleles or groups, and KIR-
HLA ligand pairs was not associated with HIV acquisition
in logistic regression models (Table 1).
Presence of the KIR haplotype BB is associated with lower
viral loads during HIV infection and higher CD4+ T-cell
counts
To test whether KIR or HLA are associated with differ-
ences in the course of disease we used a linear mixed
model approach to model post-infection viral loads ac-
counting for differences in times of viral load or CD4+ T-
cell count measurement and inter-participant variation
amongst 139 women.
The presence of KIR haplotype BB was significantly as-
sociated with lower viral loads (overall effect: −0.44log10
copies/ml, p = 0.03, Table 2 and Fig. 2a). This observa-
tion was consistent regardless of the cohort from which
these women were enrolled (Additional file 2: Figure
S1). Concordantly, CD4+ T-cell counts were higher in
individuals with BB compared with AA/AB haplotypes
(overall effect: +80 cells/μl, p = 0.04, Fig. 2b). Data be-
yond around 60 months of follow-up are sparse leading
to overlapping confidence intervals thereafter. Cross-
sectional analysis of viral loads supports this observation
(Additional file 3: Figure S2). Amongst 24 women for
whom CD4 + T-cell counts prior to HIV acquisition were
available, the counts did not differ according to haplo-
type (nAA = 6, nAB = 14 and nBB = 4; medianAA = 914,
medianAB = 981 and medianBB = 824 cells/μl, Kruskal-
Wallis rank sum test χ2 = 1.8, p = 0.4) and the time of en-
rolment following HIV acquisition did not significantly
differ between groups.
Classical HLA class I alleles grouped by presence/ab-
sence of Bw4/Bw6 epitopes or C1/C2 groups were not,
on their own, associated with course of viraemia but
previously reported protective HLA alleles (B*13:02,
B*27, B*57, B*58:01 or B*81:01) tended to be associated
with lower viral loads (effect: −0.27 log10 copies/ml p =
0.10), and harmful alleles (B*18:01, B*35 or B*58:02) with
higher viral loads (effect: +0.25 log10 copies/ml p = 0.06,
Additional file 4: Figure S3). Inclusion of HLA alleles in
the model did not attenuate association between KIR
and course of HIV viraemia.
Allelic state of KIR2DL2/KIR2DL3 may explain KIR genotype
effects on HIV viral loads
Next, we examined whether the presence of specific KIR
on the B haplotype may explain the observation above.
In contrast to previous reports, the absolute number of
activating or inhibitory KIR-ligand pairs did not associ-
ate with HIV viraemia (data not shown). However, the
presence of KIR2DL2 was associated with reduced HIV
viral loads through the first 3–4 years of HIV and con-
versely, the presence of one or two copies of KIR2DL3
was significantly associated with elevated HIV viral loads
(+0.33 and +0.46 log10 copies/ml respectively relative to
KIR2DL2/KIR2DL2, p = 0.02).
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Table 1 Results of logistic regression model of KIR/HLA and HIV acquisition
HIV- (n = 155) HIV+ (n = 154) pa ORa 95 % CIa
- + + % - + + %
KIR loci
KIR2DL1 4 151 97.4 % 0 154 100.0 % 0.98 - -
KIR2DL2 45 110 71.0 % 46 107 69.9 % 0.89 1.04 0.63–1.71
KIR2DL2/KIR2DL2 39 25.5 % 35 22.9 %
KIR2DL2/KIR2DL3 70 45.8 % 72 47.1 % 0.63 1.15 0.43–2.05
KIR2DL3/KIR2DL3 44 28.8 % 46 30.1 % 0.83 1.07 0.32–2.00
KIR2DL3 40 114 74.0 % 35 118 77.1 % 0.61 1.15 0.68–1.94
KIR2DL4 3 152 98.1 % 0 154 100.0 % 0.98 - -
KIR2DL5 44 111 71.6 % 56 98 63.6 % 0.18 0.72 0.44–1.16
KIR3DL1 0 155 100.0 % 0 154 100.0 % - - -
KIR3DL1/KIR3DL1 145 94.8 % 141 92.2 %
KIR3DL1/KIR3DS1 8 5.2 % 12 7.8 % 0.27 1.69 0.62-4.04
KIR3DS1/KIR3DS1 0 0.0 % 0 0.0 % - - -
KIR3DS1 145 8 5.2 % 141 12 7.8 % 0.27 1.69 0.67–4.45
KIR3DL2 0 155 100.0 % 0 154 100.0 % - - -
KIR3DL3 2 153 98.7 % 0 154 100.0 % 0.98 - -
KIR2DS1 135 18 11.8 % 130 24 15.6 % 0.23 1.51 0.78–2.96
KIR2DS2 63 92 59.4 % 60 94 61.0 % 0.56 1.15 0.72–1.83
KIR2DS3 104 51 32.9 % 111 43 27.9 % 0.43 0.82 0.50–1.34
KIR2DS3/KIR2DS3 29 25.9 % 24 24.2 %
KIR2DS3/KIR2DS5 22 19.6 % 19 19.2 % 0.77 1.13 0.49–2.60
KIR2DS5/KIR2DS5 61 54.5 % 56 56.6 % 0.77 1.11 0.57–2.14
KIR2DS5 72 83 53.5 % 79 75 48.7 % 0.47 0.85 0.54–1.33
KIR2DS4b 2 153 98.7 % 1 153 99.4 % 0.63 1.80 0.17–39.03
197/. 23 20.2 % 11 19.0 %
197/219 31 27.2 % 25 43.1 % 0.25 1.57 0.70–4.21
./219 60 52.6 % 22 37.9 % 0.55 1.56 0.32–1.87
KIR Haplotype
Bx 33 121 78.6 % 40 113 73.9 % 0.45 0.81 0.48–1.39
AA 33 21.4 % 40 26.1 %
AB 77 50.0 % 78 51.0 % 0.65 0.88 0.50–1.55
BB 44 28.6 % 35 22.9 % 0.27 0.70 0.36–1.33
HLA Groups
Protective B alleles 122 33 21.3 % 128 26 16.9 % 0.33 0.75 0.42–1.33
Harmful B alleles 108 47 30.3 % 104 50 32.5 % 0.80 1.07 0.66–1.73
Bw4 109 46 29.7 % 103 51 33.1 % 0.50 1.18 0.73–1.92
Bw6 75 80 51.6 % 77 77 50.0 % 0.70 0.92 0.58–1.44
C1/C1 21 13.5 % 18 11.7 %
C1/C2 68 43.9 % 73 47.4 % 0.76 1.35 0.65–2.81
C2/C2 66 42.6 % 63 40.9 % 0.70 1.18 0.56–2.52
KIR/HLA Ligand Pair
KIR2DL1_C2 33 122 78.7 % 25 129 83.8 % 0.22 1.44 0.81–2.59
KIR2DS1_C2 140 15 9.7 % 132 22 14.3 % 0.15 1.68 0.84–3.46
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The extensive linkage disequilibrium between KIR genes
(Fig. 2c), can be leveraged to further understand this obser-
vation. Contrasting direction of effect between KIR2DL2
and KIR2DL3 and concordant protective effect of KIR2DS2
supports their involvement in HIV viral control because
KIR2DL2 and KIR2DL3 segregate as alleles of the same
locus and KIR2DL2 and KIR2DS2 are in moderate linkage
disequilibrium. Intriguingly, KIR2DL2/KIR2DL3 hetero-
zygous individuals have viral loads that are similar to
KIR2DL3/KIR2DL3 homozygous individuals suggesting
that even one copy of KIR2DL3 is associated with ele-
vated viraemia (Fig. 2d). A similar observation is noted
when examining CD4+ T-cell counts (Fig. 2b). These
data are consistent with the observation that BB haplo-
types of KIR are associated with reduced viraemia as
KIR2DL2 is a constituent of the B haplotype.
To assess whether KIR-ligand interactions may be in-
volved we examined HIV viral loads according to gene
content at the KIR2DL2/KIR2DL3 locus and their li-
gands: HLA alleles of the C1/C2 groups (Additional file
5: Table S1). Linear mixed models testing for an inter-
action between KIR2DL2/KIR2DL3 locus gene content
and the number of HLA C1/C2 ligands did not provide
evidence of statistical interaction. Graphical examination
of viral load measures and CD4+ T-cell counts support
this interpretation (Additional file 6: Figure S4). Al-
though larger studies may reveal nuanced effects, given
the observations here the association between KIR2DL2/
KIR2DL3 and HIV viraemia does not appear to be dis-
cernably modified by HLA C1/C2 ligands.
Discussion
KIR and HLA haplotypes have been associated with HIV
disease outome, but little is known about their role in HIV
acquisition. Using a large cohort of prospectively enrolled
women at risk for HIV, we did not observe evidence of as-
sociation between KIR profiles and HIV-1 acquisition.
This finding is consistent with recent studies that suggest
that genetic variation does not explain a substantial pro-
portion in liability to acquire HIV-1 [33, 34]. In contrast,
we found that KIR genotype BB, which encodes KIR2DL2,
was associated with lower HIV viraemia and higher CD4+
Table 1 Results of logistic regression model of KIR/HLA and HIV acquisition (Continued)
KIR2DL2_C1 90 65 41.9 % 92 62 40.3 % 0.77 0.93 0.59–1.47
KIR2DL3_C1 94 61 39.4 % 85 69 44.8 % 0.43 1.20 0.76–1.90
KIR3DL1_Bw4 109 46 29.7 % 103 51 33.1 % 0.50 1.18 0.73–1.92
KIR3DS1_Bw4 150 5 3.2 % 148 6 3.9 % 0.68 1.29 0.38–4.59
KIR2DS4_Cw04 128 27 17.4 % 128 26 16.9 % 0.86 1.04 0.57–1.91
KIR3DL2_A3A11 134 21 13.5 % 133 21 13.6 % 0.98 1.01 0.52–1.95
Previous Presentations: A part of these data was presented at the International Immunogenetics and HLA Workshop 2012. Liverpool, UK, 28 May-3 June 2012
a(adjusted for tenofovir gel use)
bFor a subset (172/309, 56 %) KIR2DS4 alleles were genotyped where 197 denotes the common deletion variant of KIR2DS4 that has a 22 bp deletion in exon 5
Table 2 linear mixed-effects model results for association between
KIR/HLA and HIV viraemia in 139 women with incident HIV infection













KIR2DL2/KIR2DL2 4.08 Ref 0.15 0.02
KIR2DL2/KIR2DL3 0.33 0.16
KIR2DL3/KIR2DL3 0.46 0.17
KIR2DL5 4.43 −0.13 0.13 0.32
KIR3DL1/KIR3DL1 4.33 Ref 0.10 0.84
KIR3DL1/KIR3DS1 −0.05 0.24
KIR3DS1/KIR3DS1 - - -
KIR2DS1 4.36 −0.13 0.19 0.47
KIR2DS2 4.53 −0.28 0.13 0.03
KIR2DS3/KIR2DS3 4.03 Ref 0.19 0.14
KIR2DS3/KIR2DS5 0.01 0.25
KIR2DS5/KIR2DS5 0.33 0.20
KIR2DS4 4.43 −0.08 0.77 0.91
HLA groups
Protective HLA-B alleles 4.38 −0.27 0.17 0.10
Harmful HLA-B alleles 4.26 0.25 0.13 0.06
Bw4 4.33 0.07 0.14 0.63
Bw6 4.39 −0.08 0.13 0.52
Number of C1 epitopes 4.40 −0.08 0.09 0.40
Number of C2 epitopes 4.25 0.07 0.09 0.43
Random Effects Variance SD
Weeks postinfection (Intercept) 0.02 0.12
X002PID (Intercept) 0.61 0.78
Residual 0.31 0.55
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T-cell counts sustained over more than 5 years in a cohort
of more than 130 prospectively followed South African
women from a homogenous ethnic background.
Lack of association between KIR haplotype and HIV-
1 acquisition observed here are in contrast to previous
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Fig. 2 KIR haplotype BB is associated with a lower VL and b higher CD4+ T-cell counts in primary HIV infection. c The linkage-disequilibrium between
KIR genes. d KIR2DL2 is associated with lower viral loads whilst KIR2DL3 (homozygous or heterozygous) is associated with relatively higher viral loads.
Each plot shows the individual viral load or CD4 count measure as well as a LOWESS -smoothed curve fitted to the data as well as the 95 % confidence
interval for the curve (grey shading adjacent to coloured lines)
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receptor repertoires, and the presence of KIR3DS1 in par-
ticular, and genotype AB, with reduced HIV acquisition
[10]. The KIR3DS1 gene is infrequent in the population
under study, which is typical for populations of African
descent [35]. Our study, despite being larger than previous
studies, was powered to identify covariates with unadjusted
odds ratio <0.63 or >1.6, hence we may commit type 2
error if true effect sizes exist and are smaller. Although not
feasible here, a more robust strategy would have been a
prospective cohort analysis.
The association between KIR and HIV disease course is
in agreement with immunogenetic [5] and functional
studies [36] as well as recent evidence that NK cell func-
tion is a feature of HIV-1 control in patients with poor
CD8+ T-cell responses [37]. Similarly, in HCV and HTLV-
1 infection KIR2DL2 modifies HLA mediated effects on
disease and is thereby implicated in protective responses
[20]. However, our data are in contrast with observations
reported by Khakoo et al. on Hepatitis C infection, where
KIR2DL3 homozygous individuals had superior resolution
[38]. These different outcomes may be explained by dif-
ferences in pathogenesis between HCV and HIV-1. Our
findings are also in contrast to a previous report of
lower CD4+ T-cell counts in HIV infected KIR haplo-
type B carriers [39]. However, this apparent discrepancy
may be due to cross-sectional sampling in Jennes et al.
[39] leading to a frailty bias in selection of participants
and consequent reversal of direction of effect as was re-
cently observed in a separate study [33]. Gaudieri et al.
also reported that carriage of either of the haplotype B
genes KIR2DS2 or KIR2DL2 was associated with more
rapid CD4+ T-cell decline, but they did not specifically as-
sess the combined haplotype [40]. Nevertheless, these
findings suggest the potential for population heterogeneity
in effect and highlight the challenges in confidently delin-
eating which KIR gene contributes to the haplotype effect.
Several underlying mechanisms may be involved in
KIR2DL2 mediated enhancement of HIV control, or re-
ciprocally of KIR2DL3 impairment. Firstly, the presence
of KIR2DL2 associated footprints in virus sequenced from
KIR2DL2+ donors supports a model in which KIR2DL2
may bind HIV-derived viral peptides presented by HLA-C
[17]. In vitro studies using viral peptide variants suggest
that selected viral peptides enhance KIR2DL2 binding,
resulting in NK cell inhibition and diminished degranula-
tion, hence affording the virus a selection advantage [41].
This may explain why the beneficial effect of KIR2DL2
may be lost later in infection. Whilst differing by only a
few amino acids, KIR2DL2 has been reported to have
higher affinity for HLA-CI than KIR2DL3, and KIR2DL2/
2DL3 differ in their sensitivity to peptide bound in the
HLA C groove offering a further potential explanation for
how subtle differences may explain the divergent effects
of KIR2DL2/L3 [42]. Although Korner et al. [15], show
that KIR2DL2+ NK cells are functionally more potent
in the presence of HLA-C1/C1, because KIR2DL2 me-
diates inhibitory signals following binding to HLA-C
molecules of both HLA-C1 or HLA-C2, the absence of
an interaction between KIR2DL2 and HLA-C1/C2 group
in our study is compatible with this model [43]. The link-
age disequilibrium that we found between KIR2DL2 and
KIR2DS2 was consistent with previous studies [44] and im-
plies that a role for KIR2DS2 cannot be excluded. An alter-
native mechanism is suggested by Schonberg et al. [43]
who report that due to differences in timing of KIR2DL2
and KIR2DL1 expression, the presence of KIR2DL2 may
affect ligand-instructed NK cell education during develop-
ment. Finally, KIR2DL2 may act indirectly to alter T-cell
recognition of virally infected cells as described in HTLV-1
and HCV infection [20].
Blockade of inhibitory KIR interaction with HLA-C
has been pursued as therapeutic strategy in malignancy
and viral infection [45]. An antibody that blocks inter-
action of KIR2DL1/L2/L3/S1/S2 (1-7 F9) with HLA-C,
was shown to enhance degranulation of NK cells from
HIV infected donors cocultured with target cells in vitro
[46]. The enhancement in NK cell degranulation ob-
served with 1-7 F9 was higher amongst NK cells from
donors with KIR haplotype B in congruence with our
observations. However, precise delineation of the role of
KIR2DL2, KIR2DL3 and KIR2DS2 is difficult. This ap-
proach has been further developed in acute myeloid leu-
kaemia (AML), multiple myeloma (MM) and lymphoma
models [47–49]. A humanised version (lirilumab) was
shown to be safe [50] in humans and is currently in clin-
ical trials for treatment of AML (NCT01687387), MM
(NCT02252263, NCT01592370), lymphoma (NCT01592
370) and some solid organ tumours (NCT01750580, NC
T01714739). We speculate that similar approaches may
be beneficial in HIV.
In spite of having a pre-determined data analysis plan
and consistent viral load and CD4+ T-cell measures across
both sub-cohorts, we cannot exclude that this finding is a
false positive due to multiple comparisons. Larger studies,
that limit analyses to replication of this finding, are re-
quired. In addition, this study has other noteworthy limita-
tions. Firstly, it is limited by the lack of resolution of
specific KIR alleles and copy number. Secondly, in the case
control analysis we were unable to account for the trans-
mitting partners KIR status constraining our ability to con-
firm previous reports of KIR2DS4*001 carriage in the
transmitting partner being linked to enhanced transmis-
sion risk [51]. Thirdly, the limited sample size prohibited
subgroup analyses, for example, of HLA C1/C2 ligand in-
teractions. Finally, we were unable to link these clinical ob-
servations with previously reported flow-cytometry based
measures of NK cell function [23] due to the absence of
KIR2DL2/L3 specific antibodies used in our previous work.
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Conclusions
Our data suggest that KIR2DL2 on the B KIR haplotype
may mediate measurable control of HIV viraemia and un-
derlies a protective effect through the early years of chronic
HIV infection. Larger studies are required to confirm this
finding and establish its generalizability. These data also
support exploration of using KIR-blocking approaches to
manipulate NK cell function in HIV infection.
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